Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 2 |
2021 | 3 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Pharmacoeconomics. 2021 Sep;39(9):1045-1058. doi: 10.1007/s40273-021-01027-4. Epub 2021 Jun 9.
Pharmacoeconomics. 2021.
PMID: 34105083
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.
Stellato D, Thabane ME, Chandiwana D, Park J, Delea TE.
Stellato D, et al.
Pharmacoeconomics. 2021 Jul;39(7):853-867. doi: 10.1007/s40273-021-01028-3. Epub 2021 May 18.
Pharmacoeconomics. 2021.
PMID: 34002341
Item in Clipboard
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2- Advanced Breast Cancer.
Stellato D, Thabane M, Eichten C, Delea TE.
Stellato D, et al.
Curr Oncol. 2021 Jan 14;28(1):491-508. doi: 10.3390/curroncol28010051.
Curr Oncol. 2021.
PMID: 33466914
Free PMC article.
Item in Clipboard
Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective.
Stellato D, Gerbasi ME, Ndife B, Ghate SR, Moynahan A, Mishra D, Gunda P, Koruth R, Delea TE.
Stellato D, et al.
J Manag Care Spec Pharm. 2019 Nov;25(11):1227-1237. doi: 10.18553/jmcp.2019.25.11.1227.
J Manag Care Spec Pharm. 2019.
PMID: 31663466
Free PMC article.
Item in Clipboard
Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi ME, Stellato D, Ghate SR, Ndife B, Moynahan A, Mishra D, Gunda P, Koruth R, Delea TE.
Gerbasi ME, et al. Among authors: stellato d.
J Med Econ. 2019 Dec;22(12):1243-1252. doi: 10.1080/13696998.2019.1635487. Epub 2019 Aug 4.
J Med Econ. 2019.
PMID: 31223037
Free article.
Item in Clipboard
Cite
Cite